132 related articles for article (PubMed ID: 3678318)
21. Sex hormone binding globulin and risk factors for breast cancer in a population of normal women who had never used exogenous sex hormones.
Moore JW; Key TJ; Bulbrook RD; Clark GM; Allen DS; Wang DY; Pike MC
Br J Cancer; 1987 Nov; 56(5):661-6. PubMed ID: 3426933
[TBL] [Abstract][Full Text] [Related]
22. Influence of menstrual cycle, parity and oral contraceptive use on steroid hormone receptors in normal breast.
Battersby S; Robertson BJ; Anderson TJ; King RJ; McPherson K
Br J Cancer; 1992 Apr; 65(4):601-7. PubMed ID: 1562470
[TBL] [Abstract][Full Text] [Related]
23. The relation between radiographic features and determinants of risk of breast cancer.
Gravelle IH; Bulstrode JC; Wang DY; Bulbrook RD; Hayward JL
Br J Radiol; 1980 Feb; 53(626):107-13. PubMed ID: 7370490
[TBL] [Abstract][Full Text] [Related]
24. Abnormalities in evening plasma prolactin levels in nulliparous women with benign or malignant breast disease.
Tarquini A; di Martino L; Malloci A; Kwa HG; van der Gugten AA; Bulbrook RD; Wang DY
Int J Cancer; 1978 Dec; 22(6):687-90. PubMed ID: 721323
[TBL] [Abstract][Full Text] [Related]
25. An abnormal luteal-phase evening peak of plasma prolactin in women with a family history of breast cancer.
Kwa HG; Wang DY
Int J Cancer; 1977 Jul; 20(1):12-4. PubMed ID: 561758
[TBL] [Abstract][Full Text] [Related]
26. The association of height, weight, menstrual and reproductive events with breast cancer: results from two prospective studies on the island of Guernsey (United Kingdom).
De Stavola BL; Wang DY; Allen DS; Giaconi J; Fentiman IS; Reed MJ; Bulbrook RD; Hayward JL
Cancer Causes Control; 1993 Jul; 4(4):331-40. PubMed ID: 8347782
[TBL] [Abstract][Full Text] [Related]
27. Reliability of serum prolactin measurements in women.
Koenig KL; Toniolo P; Bruning PF; Bonfrer JM; Shore RE; Pasternack BS
Cancer Epidemiol Biomarkers Prev; 1993; 2(5):411-4. PubMed ID: 8220084
[TBL] [Abstract][Full Text] [Related]
28. A review of the epidemiology of human breast cancer.
Kelsey JL
Epidemiol Rev; 1979; 1():74-109. PubMed ID: 398270
[TBL] [Abstract][Full Text] [Related]
29. Differences in measured mammographic density in the menstrual cycle.
Hovhannisyan G; Chow L; Schlosser A; Yaffe MJ; Boyd NF; Martin LJ
Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):1993-9. PubMed ID: 19567508
[TBL] [Abstract][Full Text] [Related]
30. Disordered nocturnal prolactin regulation in women with breast cancer.
Malarkey WB; Schroeder LL; Stevens VC; James AG; Lanese RR
Cancer Res; 1977 Dec; 37(12):4650-4. PubMed ID: 922745
[TBL] [Abstract][Full Text] [Related]
31. Temporary increase of FSH levels in healthy, nulliparous, young women after cessation of low-dose oral contraceptive use.
Jernstrom H; Knutsson M; Olsson H
Contraception; 1995 Jul; 52(1):51-6. PubMed ID: 8521715
[TBL] [Abstract][Full Text] [Related]
32. The circadian pattern of melatonin and its positive relationship with progesterone in women.
Webley GE; Leidenberger F
J Clin Endocrinol Metab; 1986 Aug; 63(2):323-8. PubMed ID: 3722324
[TBL] [Abstract][Full Text] [Related]
33. Plasma prolactin in relation to menstrual cycle phase, oral contraceptive use, arousal time and smoking habits.
Jernström H; Knutsson M; Taskila P; Olsson H
Contraception; 1992 Dec; 46(6):543-8. PubMed ID: 1493714
[TBL] [Abstract][Full Text] [Related]
34. Pituitary-ovarian relationships preceding the menopause. I. A cross-sectional study of serum follice-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone levels.
Reyes FI; Winter JS; Faiman C
Am J Obstet Gynecol; 1977 Nov; 129(5):557-64. PubMed ID: 910845
[TBL] [Abstract][Full Text] [Related]
35. Identification of women at high risk of breast cancer.
Bulbrook RD; Hayward JL; Wang DY; Thomas BS; Clark GM; Allen DS; Moore JW
Breast Cancer Res Treat; 1986; 7 Suppl():S5-10. PubMed ID: 3742064
[TBL] [Abstract][Full Text] [Related]
36. Prolactin and breast cancer risk.
Ingram DM; Nottage EM; Roberts AN
Med J Aust; 1990 Oct; 153(8):469-73. PubMed ID: 2215338
[TBL] [Abstract][Full Text] [Related]
37. Oral contraceptives and premenopausal breast cancer in nulliparous women.
Stadel BV; Lai SH; Schlesselman JJ; Murray P
Contraception; 1988 Sep; 38(3):287-99. PubMed ID: 3168449
[TBL] [Abstract][Full Text] [Related]
38. Characteristics that predict risk of breast cancer before and after the menopause.
Paffenbarger RS; Kampert JB; Chang HG
Am J Epidemiol; 1980 Aug; 112(2):258-68. PubMed ID: 7416152
[TBL] [Abstract][Full Text] [Related]
39. Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk.
Spicer DV; Ursin G; Parisky YR; Pearce JG; Shoupe D; Pike A; Pike MC
J Natl Cancer Inst; 1994 Mar; 86(6):431-6. PubMed ID: 8120917
[TBL] [Abstract][Full Text] [Related]
40. Nyctohemeral changes in plasma prolactin levels and their relationship to breast cancer risk.
Wang DY; Sturzaker HE; Kwa HG; Verhofstad F; Hayward JL; Bulbrook RD
Int J Cancer; 1984 May; 33(5):629-32. PubMed ID: 6724738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
